ESTRO 2024 - Abstract Book

S2812

Interdisciplinary - Health economics & health services research

ESTRO 2024

6. Baškarada S, Watson J, Cromarty J. Leadership and organizational ambidexterity. J Manag Dev. 2016 Jul 11;35(6):778 – 88.

7.

Avolio B, Bass B. Instrument (Leader and Rater Form). 2020;

8. Avolio BJ, Bass BM. Multifactor leadership questionnaire (TM). Mind Gard Inc Menlo Park CA. 2004;

9. Hunt JG. Transformational/charismatic leadership’s tranformation of the field: An historical essay. Leadersh Q. 1999 Jun 1;10(2):129 – 44.

10. Batista-Foguet JM, Esteve M, van Witteloostuijn A. Measuring leadership an assessment of the Multifactor Leadership Questionnaire. PLoS ONE. 2021 Jul 22;16(7):e0254329.

1431

Digital Poster

Implementing value-based healthcare strategy for non-melanoma skin cancer

Iuliia Zuenkova 1 , Dmitry Kicha 1 , Andrey Kostin 2

1 RUDN University, Healthcare management & Public Health, Moscow, Russian Federation. 2 RUDN University, Scientific Director, Moscow, Russian Federation

Purpose/Objective:

The aim of this study was to implement value-based healthcare approach for non-melanoma skin cancer (NMSC) patients with particular focus on provision patient’s choice to all treatment modalities inside clinical guidelines, implementing patient-reported outcome measures (PROMs), patient-related experience measures (PREMs), shared decision-making (SDM), develop and apply the patient communication algorithm specific for the superficial X-ray therapy treatment (sXRT).

Material/Methods:

The oncology clinic with all applicable for NMSC treatment modalities (surgery incision, XRT, photodynamic, topical agents) was selected and the patient pathway was restructured. The oncodermatology center included a unified coordination center, a single symptom-to-treatment patient route, availability of all diagnostic and treatment modalities, omnichannel patient communication. An observational, incomparable, prospective, long-term single center cohort study of the patient reported outcome measures (PROMs) and patient related experience measures (PREMs) was conducted from December 2020 to September 2021. 42 patients aged 42-82 have passed all stages of the study. Inclusion criteria: NMSC patients, stage 1-2, lesion size <2 cm, face location, clinical indications for at least two treatment methods - sXRT and surgery. Exclusion criteria: other skin cancers, NMSC > 2 cm, location other than face, 3-4 stages. FACE-Q SKIN CANCER MODULE – APPEARANCE-RELATED DISTRESS© was used as PROMs tool and considered when choosing treatment modality. SDM (The Three-talk model) was used to discuss treatment choices